Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Medical Products Laboratories, Inc.
WARNING LETTER
•Medical Products Laboratories, Inc.•October 16, 2025

Medical Products Laboratories, Inc. – FDA Warning Letter, Oct 16, 2025

Record Details

Medical Products Laboratories, Inc. received a warning letter from the FDA following an inspection of its Philadelphia facility conducted between September 29 and October 16, 2025. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations and the Federal Food, Drug, and Cosmetic Act. A primary concern was the firm’s failure to prevent microbiological contamination; the company reportedly used unvalidated treatments to reduce bacteria levels and released products that failed contamination tests. Additionally, the FDA found that the company did not adequately validate its manufacturing processes, often relying on incomplete data or studies from different facilities. Quality investigations into product failures—including subpotent test results and customer complaints about product crystallization—were also found to be insufficient. The agency further identified several products, such as Hydro-Q Gel and various Sodium Sulfacetamide and Sulfur formulations, as unapproved new drugs that were being marketed without required FDA authorization. Finally, the company’s stability program lacked the scientific data necessary to support its labeled storage conditions and expiration dates. To address these issues, the FDA requires the company to perform comprehensive risk assessments for all distributed products, remediate its manufacturing and stability protocols, and engage a qualified independent consultant to audit its operations. The firm must provide a detailed written response within 15 working days outlining its corrective actions and plans to ensure future compliance.

Company
Medical Products Laboratories, Inc.
Inspection date
October 16, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Tina Smith (Director)
View Company Profile

ID · 319e930f-6222-41bb-9be6-019b24ec0895

Violation Codes10
21 CFR 211.113(a)FD&C Act 501(a)(2)(B)21 U.S.C. 331(dd)21 U.S.C. 356c(a)21 CFR 211FD&C Act 201(p)21 U.S.C. 35521 CFR 211(c)(2)FD&C Act 201(g)(1)21 CFR 210

Full citation text and observation details available on the Dashboard.

Other documents for Medical Products Laboratories, Inc.
  • 483 - 2025-10-16October 16, 2025
  • 483 - 2023-07-13July 13, 2023
  • EIR - 2020-03-13March 13, 2020
  • 483 - 2020-03-13March 13, 2020
  • EIR - 2017-10-12October 12, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Medical Products Laboratories, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.